Last10K.com

Ac Immune Sa (ACIU) SEC Filing 20-F Annual report for the fiscal year ending Tuesday, December 31, 2019

SEC Filings

ACIU Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ACIU Annual Reports

    20-F Annual Report March 2022
    20-F Annual Report March 2021
  • 20-F Annual Report March 2020
    • 20-F Annual Report March 2019
    20-F Annual Report March 2018
    20-F Annual Report March 2017

ACIU Corporate News

Ac Immune Sa

HISTORY TOOLS
CIK: 1651625 Ticker: ACIU

View differences made from one year to another to evaluate Ac Immune Sa's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ac Immune Sa.

Continue

Assess how Ac Immune Sa's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ac Immune Sa's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Document And Entity Information
Balance Sheets
Statements Of Cash Flows
Statements Of Cash Flows (Parenthetical)
Statements Of Changes In Equity
Statements Of Comprehensive Income/(Loss)
Statements Of Income/(Loss)
Basis Of Preparation
Basis Of Preparation (Details)
Capital Risk Management
Cash And Cash Equivalents And Financial Assets
Cash And Cash Equivalents And Financial Assets (Tables)
Cash And Cash Equivalents And Financial Assets, Cash And Cash Equivalents (Details)
Cash And Cash Equivalents And Financial Assets, Cash And Cash Equivalents And Short-Term Financial Assets (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Commitments And Contingencies (Tables)
Earnings Per Share
Earnings Per Share (Details)
Earnings Per Share (Tables)
Expenses By Category
Expenses By Category (Details)
Expenses By Category (Tables)
Financial Instruments And Risk Management
Financial Instruments And Risk Management (Details)
Financial Instruments And Risk Management (Tables)
Financing Obligation
Financing Obligation (Details)
General Information
General Information (Details)
Income Taxes
Income Taxes (Details)
Income Taxes (Tables)
Income Taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses And Unused Tax Credits (Details)
Other Current Receivables
Other Current Receivables (Details)
Other Current Receivables (Tables)
Prepaid Expenses And Accrued Income
Prepaid Expenses And Accrued Income (Details)
Prepaid Expenses And Accrued Income (Tables)
Property, Plant And Equipment
Property, Plant And Equipment (Details)
Property, Plant And Equipment (Tables)
Related-Party Transactions
Related-Party Transactions (Details)
Related-Party Transactions (Tables)
Retirement Benefit Plan
Retirement Benefit Plan (Details)
Retirement Benefit Plan (Tables)
Retirement Benefit Plan, Actuarial Assumptions And Sensitivity Analysis (Details)
Retirement Benefit Plan, Change In Net Defined Benefit Liability (Details)
Retirement Benefit Plan, Change In Other Comprehensive Loss (Details)
Retirement Benefit Plan, Changes In Defined Benefit Obligation (Details)
Retirement Benefit Plan, Changes In Fair Value Of Plan Assets (Details)
Revenues
Revenues (Tables)
Revenues, 2015 Grant From The Michael J. Fox Foundation (Details)
Revenues, Alpha-Synuclein And Tdp-43 Pet Tracers In Ad - 2016 Agreement With Biogen (Details)
Revenues, Anti-Abeta Antibody In Ad - 2006 Agreement With Genentech (Details)
Revenues, Anti-Tau Antibody In Ad - 2012 Agreement With Genentech (Details)
Revenues, Changes In Contract Assets And Liabilities (Details)
Revenues, Contract Revenue Attributable To Licensing Arrangements (Details)
Revenues, Recognized Revenues (Details)
Revenues, Recombinant Protein Therapeutic Candidate -2017 Agreement With Essex Bio-Technology Limited (Details)
Revenues, Tau Morphomer Small Molecule - 2018 License Agreement With Eli Lilly And Company (Details)
Revenues, Tau Vaccine In Ad - 2014 Agreement With Janssen Pharmaceuticals (Details)
Revenues, Tau-Pet Imaging Agent In Ad -2014 Agreement With Life Molecular Imaging (Formerly Piramal Imaging Sa) (Details)
Right-Of-Use Assets And Lease Liabilities
Right-Of-Use Assets And Lease Liabilities (Details)
Right-Of-Use Assets And Lease Liabilities (Tables)
Share Capital
Share Capital (Details)
Share Capital (Tables)
Share Capital, Convertible Note Agreement An Follow-On Offerings (Details)
Share Capital, Shelf Registration Statement (Details)
Share-Based Compensation
Share-Based Compensation (Tables)
Share-Based Compensation, Non-Vested Share Awards (Details)
Share-Based Compensation, Outstanding Options, Range Of Exercise Prices And Expiration Dates (Details)
Share-Based Compensation, Plans Outstanding (Details)
Share-Based Compensation, Weighted Average Exercise Prices (Details)
Share-Based Compensation, Weighted Average Grant Date Fair Value And Assumptions (Details)
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies, Accounting Pronouncements Recently Adopted (Details)
Trade Payables And Accrued Liabilities
Trade Payables And Accrued Liabilities (Details)
Trade Payables And Accrued Liabilities (Tables)
Ticker: ACIU
CIK: 1651625
Form Type: 20-F Annual Report
Accession Number: 0000950103-20-006219
Submitted to the SEC: Mon Mar 30 2020 9:04:58 AM EST
Accepted by the SEC: Mon Mar 30 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aciu/0000950103-20-006219.htm